A Phase 1/2 Study of BA3071 in Patients With Solid Tumors
Latest Information Update: 30 May 2025
At a glance
- Drugs BA 3071 (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors BioAtla
Most Recent Events
- 06 May 2025 According to a BioAtla media release, Phase 1 and phase 2 data read-outs are ongoing across solid tumor types (median of 3 prior lines of treatment).
- 27 Mar 2025 According to a BioAtla media release, company initiated partnering discussions Q1 2025.
- 01 Oct 2024 According to a BioAtla media release, data to be presented as oral presentation at the Society for Melanoma Research 21st International Congress (SMR) in October 10 - 13, 2024, in New Orleans, LA.